Brachytherapy Devices Market - By Product Type (Seeds, Applicators and Afterloaders, Electronic Brachytherapy), By Technique (High Dose Rate [HDR], Low Dose Rate [LDR]), By Application (Gynecological Cancer, Prostate Cancer), By End-use - Global Forecast,

Brachytherapy Devices Market - By Product Type (Seeds, Applicators and Afterloaders, Electronic Brachytherapy), By Technique (High Dose Rate [HDR], Low Dose Rate [LDR]), By Application (Gynecological Cancer, Prostate Cancer), By End-use - Global Forecast, 2023-2032

Global brachytherapy devices market size will grow at a 6.2% CAGR from 2023 to 2032. The increasing incidence of cancer worldwide, especially prostate and cervical cancers, is boosting demand for brachytherapy procedures, driving industry growth.

Additionally, advancements in technology are leading to more precise and efficient brachytherapy devices, reducing side effects and treatment durations. Elekta AB, based in Stockholm, Sweden, unveiled its inventive interventional radiotherapy solutions at Arab Health 2021. These solutions, personalized for cancer care and brain disorders, were designed primarily to target tumors while ensuring patient safety.

The growing awareness about the benefits of minimally invasive cancer treatment options will further drive business growth. Favorable reimbursement policies and a rising aging population will also fuel market expansion.

The brachytherapy devices market is categorized based on product type, technique, application, end-use, and region.

The electronic brachytherapy product segment will reflect a 6.5% CAGR over 2023-2032. The non-invasive nature of electronic brachytherapy, its reduced radiation exposure to healthy tissues, and shorter treatment times will drive growth in the segment. Moreover, technological advancements in electronic brachytherapy devices contribute to its rising popularity as a preferred treatment option for various cancers.

The high dose rate (HDR) technique will exhibit a 5.8% CAGR through 2032, driven by its precision, shorter treatment duration, and reduced radiation exposure to healthy tissues. These advantages will make HDR brachytherapy an increasingly preferred choice for cancer treatment in the coming years.

Based on application, the breast cancer segment is anticipated to depict a 6% CAGR from 2023 to 2032, driven by factors such as the increasing incidence of breast cancer, demand for minimally invasive treatments, and the ability of brachytherapy to provide targeted and effective radiation therapy for breast cancer patients.

Regionally, the Europe brachytherapy devices industry will grow at a 6.3% CAGR through 2032, driven by factors such as the rising prevalence of cancer, favorable reimbursement policies, and increasing adoption of advanced medical technologies in the region. The rising focus on minimizing the side effects of radiation therapy will further augment growth in the regional industry.